This application addresses broad Challenge Area (03) Biomarker Discovery and Validation and specific Challenge Topic, 03-AR-103: Biomarkers: Bench to Bedside for Autoimmune and Inflammatory Skin and Rheumatic Diseases. Some patients with humoral autoimmune disorders who present with hyperactive responses to B cell receptor triggering are postulated to have a defect in the sialic acid acetylesterase (SIAE)/Siglec pathway of peripheral B cell tolerance. Patients with defects in this pathway may be candidates for novel therapies entailing either a """"""""biologic"""""""" replacement with human SIAE or the possible use of small molecule inhibitors to an enzyme that functionally opposes the activity of SIAE,. The value and validity of two novel biomarkers in subjects with humoral autoimmune disorders will be investigated. We predict that a subset of patients with systemic lupus erythematosus or with rheumatoid arthritis may exhibit decreased levels of SIAE in the serum or plasma, and/or increased expression of 9-Oacetyl sialic acid on the surface of B cells. Studies are proposed to determine whether these biomarkers correlate with enhanced B cell receptor signaling, or SIAE mutations. If decreased Lyn levels are seen in B cells in some patients it is predicted that enhanced 9-O-acetylation will not be found in individuals with deficient Lyn. A negative correlation with the PTPN22 620W variant is also expected and this will be analyzed.

Public Health Relevance

These studies explore the value of two novel biomarkers in distinguishing patients with lupus and rheumatoid arthritis who may be candidates for a novel approach to therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
NIH Challenge Grants and Partnerships Program (RC1)
Project #
1RC1AR058481-01
Application #
7830671
Study Section
Special Emphasis Panel (ZRG1-IMM-E (58))
Program Officer
Mancini, Marie
Project Start
2009-09-23
Project End
2011-08-31
Budget Start
2009-09-23
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$499,771
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Chellappa, Vasant; Taylor, Kendra N; Pedrick, Kathryn et al. (2013) M89V Sialic acid Acetyl Esterase (SIAE) and all other non-synonymous common variants of this gene are catalytically normal. PLoS One 8:e53453
Pillai, Shiv; Netravali, Ilka Arun; Cariappa, Annaiah et al. (2012) Siglecs and immune regulation. Annu Rev Immunol 30:357-92
Hirschfield, G M; Xie, G; Lu, E et al. (2012) Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun 13:328-35
Pillai, Shiv; Mattoo, Hamid; Cariappa, Annaiah (2011) B cells and autoimmunity. Curr Opin Immunol 23:721-31
Pillai, Shiv; Cariappa, Annaiah (2009) The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 9:767-77